Merck (MRK) Q3 2025 earnings summary

Executive summary

• Achieved solid organic growth across all sectors in Q3 2025, with group revenues up 5.2% organically and total net sales rising 1.0% year-over-year despite significant FX headwinds.

• Life Science and Healthcare led growth, with Life Science organic sales up 5.9–6% and Healthcare benefiting from the SpringWorks acquisition.

• SpringWorks acquisition consolidated for the first time, contributing to Healthcare's portfolio and establishing Rare Diseases as a new strategic pillar.

• Surface Solutions divestment completed, supporting margin improvement in Electronics.

• Full-year 2025 guidance confirmed and narrowed, reflecting increased visibility and resilience amid FX and macroeconomic risks.

Financial highlights

• Q3 2025 net sales rose to €5.318 billion, with organic growth of €273 million offset by FX headwinds of €-256 million.

• EBITDA pre increased 3.1% to €1.669 billion, margin up to 31.4%; EBIT up 11.3% to €1.221 billion.

• EPS pre rose 0.9% to €2.32; reported EPS up 11.3% to €2.07; profit after tax up 10.6% to €898 million.

• Operating cash flow up 4.1% to €1.518 billion; net financial debt increased 29.8% to €9.288–9.29 billion due to acquisition financing.

• Gross profit for Q3 was €3.213 billion, up 2.2% year-over-year.

Outlook and guidance

• Full-year 2025 group sales guidance narrowed to €20.8–21.4 billion, midpoint €21.1 billion; organic net sales growth guidance at ~3%.

• EBITDA pre guidance narrowed to €6–6.2 billion, midpoint €6.1 billion; organic EBITDA pre growth now 5–10%.

• EPS pre guidance set at €8.20–8.60; operating cash flow forecast at €3.6–4.0 billion.

• Life Science organic sales growth forecast at 4–5%; Healthcare at ~3% plus portfolio effect; Electronics at -3% to -1%.

• Portfolio effects from SpringWorks and Surface Solutions expected to be positive for sales but slightly negative for EBITDA pre.